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Major differences are evident between Japanese and Western
practice in the prevention of gastrointestinal injury caused
by low-dose aspirin (LDA) and nonsteroidal anti-inflammatory
drugs (NSAIDs). The proportion of physicians prescribing gastro-
protective agents with NSAIDs and LDA with the aim of pre-
venting gastrointestinal injury is 77% in Japan(1) and between 70-
84% in Spain,(2) showing the great majority prescribe something to
protect the stomach in both countries. The gastroprotective agent
prescribed, however, is a proton pump inhibitor (PPI) in 99.4% of
cases in Spain,(2) whereas in Japan only 37% of prescriptions are
for a PPI, with a similar proportion for cytoprotective agents (CP).
If we include combination therapy with a PPI or H2-receptor
antagonist (H2RA) + CP, then CP are the most commonly pre-
scribed gastroprotective agents in Japan.(1) It is not that European
physicians do not like CP, rather they are fully aware of the
gastrointestinal mucosal protective effects of CP.(3-5) PPIs are
clearly superior to CP in the prevention of upper gastrointestinal
bleeding caused by NSAIDs and LDA. However, gastrointestinal
injury caused by NSAIDs and LDA is not confined to only the
upper gastrointestinal tract (oesophagus, stomach and duodenum),
but can also involve the small and large intestines. Some CP have
been reported to prevent NSAID-associated injury to the small
intestine.(6) PPIs have few protective effects on the small intestine,
so we can anticipate that PPI + CP combination therapy will pro-
tect the entire gastrointestinal tract including the small intestinal
mucosa. Strategies for protection against damage to the gastro-
intestinal tract caused by NSAIDs and LDA will vary between
countries according to differences in medical insurance systems,
as well as differences in the availability of medical services. Each
country should produce its own strategy. In Japan, we need to
produce evidence for CP in preventing damage caused by NSAIDs
and LDA, and develop strategies stratified according to the degree
of risk of background.
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